<DOC>
	<DOCNO>NCT00158808</DOCNO>
	<brief_summary>To assess anti-PRP antibody response one month vaccination group receive fourth consecutive dose two formulation DTPw-HBV/Hib vaccine</brief_summary>
	<brief_title>Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation ; Immuno &amp; Reacto Booster Dose 15-18 Mths</brief_title>
	<detailed_description>All subject previously prim one two formulation combine DTPw-HBV/Hib vaccine . At age 10 month , 50 % group receive plain PRP challenge ass immune memory PRP . In booster study second year life , subject receive DTPw-HBV/Hib plain PRP receive DTPw-HBV booster vaccination . All subject receive booster vaccine receive primary vaccination study .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Inclusion criterion Subjects investigator believe parents/guardians comply requirement protocol . A male female least 15 month age time booster vaccination , previously receive 3dose primary vaccination , applicable , plainPRP vaccination . Free obvious health problem establish medical history clinical examination enter study . Exclusion criterion enrolment Use investigational nonregistered product study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day end 30 day administration study vaccine exception oral polio vaccine ( OPV ) . Chronic administration immunosuppressant immunemodifying drug within six month prior booster dose . Previous booster vaccination diphtheria , tetanus , pertussis , hepatitis B Hib exception plain PRP challenge . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>